CARVITOP CR 20 TAB
₹145.00
Carvitop CR 20 Tablet is a controlled-release formulation containing 20 mg of Carvedilol, a combined alpha- and beta-blocker used to manage hypertension (high blood pressure), chronic stable angina (chest pain), and heart failure. It works by relaxing blood vessels and reducing heart workload, thereby improving heart function and reducing the risk of heart-related complications.
Description
Composition:
-
Carvedilol 20 mg (Controlled-Release)
Manufacturer: Docheal Pharma Pvt Ltd
Therapeutic Class: Cardiovascular
Indications:
-
Hypertension (High Blood Pressure)
-
Heart Failure
-
Angina Pectoris (Chest Pain)
Mechanism of Action:
Carvedilol is a non-selective beta-blocker and alpha-1 blocker. It works by blocking beta-1 and beta-2 adrenergic receptors and alpha-1 receptors, leading to:
-
Relaxation of blood vessels
-
Slowing of the heart rate
-
Reduced force of heart contractions
These actions collectively lower blood pressure, reduce heart workload, and improve heart function.
Dosage and Administration:
-
Recommended Dosage: One 20 mg tablet once daily, preferably with food to enhance absorption and reduce the risk of orthostatic hypotension.
-
Administration: Swallow the tablet whole; do not chew or crush.
-
Consistency: Take at the same time each day to maintain even blood levels.
Side Effects:
Common side effects may include dizziness, fatigue, weight gain, swelling of the extremities, slow heartbeat, and gastrointestinal disturbances. Serious side effects, though rare, can include severe hypotension, bradycardia, and respiratory issues.
Precautions:
-
Liver Impairment: Use with caution in patients with liver disease; dose adjustment may be necessary.
-
Kidney Function: Monitor renal function during treatment.
-
Discontinuation: Do not abruptly discontinue; tapering may be required to avoid exacerbation of angina or hypertension.
-
Drug Interactions: Inform your doctor of all medications being taken, as Carvitop CR 20 may interact with other drugs.








Reviews
There are no reviews yet.